The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of CBG and CBD petition

20 Jun 2022 07:00

RNS Number : 3896P
Cellular Goods PLC
20 June 2022
 

Press release

 

20 June 2022

 

Cellular Goods PLC

 

('Cellular Goods' or 'the Company')

 

Launch of industry campaign to lift restrictions on advertising and marketing CBD and CBG online

 

Cellular Goods (LSE: CBX), a UK-based wellness company providing premium consumer products formulated with lab-produced cannabinoids, today announces the launch of an industry-backed petition, 'Stop the ban on advertisement of CBG and CBD products on social media and search engines', to encourage Google and Meta, as well as other leading technology and social media companies, to remove cannabigerol ("CBG") and cannabidiol ("CBD") from their list of prohibited content and allow brands to sell and advertise these products on their platforms.

 

Cellular Goods has launched the petition in partnership with seven leading companies, who together comprise 'The CBG and CBD Brands Coalition' ("the Coalition"). The companies in the Coalition are Chanelle McCoy Health, Apothem Labs, Clearly Brands, Voyager Life, Kloris, Daye and CiiTech.

 

The Coalition is calling on the public to sign the petition, to encourage Google and Meta to change their advertising and marketing policies. The petition is hosted on Change.org and is available here.

 

With over 4.6 billion people using social media, this blanket ban is limiting companies' ability to promote their CBG and CBD products to potential consumers (Source: Digiday, 2022). The ban is also strengthening misconceptions around CBG and CBD, and hampering the public's ability to access verified information about them, making it more difficult for consumers to make informed purchasing decisions and learn about their wellness benefits.

 

A growing body of scientific and anecdotal evidence has shown that CBD and CBG have a variety of wellness effects. For example, Cellular Goods' white paper, Cannabinoids for the Prevention of Aging', has shown that CBG has a host of antioxidant and anti-inflammatory properties that make it an ingredient with immense skincare potential, preventing visible signs of aging caused by UV-light exposure and inflammation.

 

Anna Chokina, Chief Executive of Cellular Goods, commented: "CBD and CBG are increasingly accepted by society as well as across multiple jurisdictions worldwide. Despite this, some leading technology and social media companies, such as Google and Meta, have implemented blanket bans for cannabinoid brands on their platforms. This anachronistic policy is limiting access to verified information about CBG and CBD, as well as affecting legitimate businesses and preventing the sector from reaching its full potential.

 

"Through this industry-backed petition we are inviting leading technology and social media companies to remove the blanket ban on the sale of CBG and CBD. Not only will this support the industry's growth, but it will also enable the industry to raise awareness so that more people can take advantage of their wellness benefits."

 

 

For further information please contact:

 

Cellular Goods

Anna Chokina

Chief Executive

Neil Thapar

Investor Relations

via Tancredi +44 207 887 7633

 

+44 787 645 5323

Tennyson Securities

Corporate Broker

Peter Krens

 

+44 207 186 9030

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 207 399 9427 

Tancredi Intelligent Communication

Media Relations

Helen Humphrey

Gabriela Amaya Garcia

Charlie Hobbs

cellulargoods@tancredigroup.com

 

+44 744 922 6720

+44 791 503 5294

+44 789 755 7112

 

About Cellular Goods PLC:

Cellular Goods is a UK-based wellness company that provides premium products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid-powered wellness products. The initial focus is on three product verticals: Function Better, Feel Better and Look Better. These three verticals encompass Cellular Goods' premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website. The Company's shares are listed on the main market of the London Stock Exchange. www.cellular-goods.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGPUUAQUPPPPB
Date   Source Headline
7th Nov 20067:02 amRNSDirector/PDMR Shareholding
25th Sep 20069:11 amRNSInterim Results
9th Aug 200610:43 amRNSAGM Statement
26th Jun 20067:01 amRNSFinal Results
28th Apr 200610:10 amRNSGrant of Options
21st Apr 200611:25 amRNSDirector/PDMR Shareholding
3rd Mar 20061:00 pmRNSAdmission to AIM-Amendment
3rd Mar 200612:23 pmRNSAdmission to AIM
7th Feb 20064:55 pmRNSSchedule 1 - Cubus Lux
7th Feb 20067:01 amRNSAcquisition
30th Sep 20051:33 pmRNSInterim Results
25th Jul 20053:25 pmRNSDirector/PDMR Shareholding
20th Jul 20057:00 amRNSOpening of a Third Casino
19th Jul 20056:09 pmRNSChange of Adviser
19th Jul 20056:09 pmRNSDirectorate Change
21st Mar 200512:07 pmRNSAnnual Report and Accounts
6th Jan 20055:52 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.